Top-Rated StocksTop-RatedNASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $9.17 -0.11 (-1.19%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$9.18 +0.02 (+0.16%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Climb Bio Stock (NASDAQ:CLYM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Climb Bio alerts:Sign Up Key Stats Today's Range$8.90▼$9.4050-Day Range$8.81▼$14.5652-Week Range$1.63▼$18.33Volume770,171 shsAverage Volume1.32 million shsMarket Capitalization$538.65 millionP/E RatioN/ADividend YieldN/APrice Target$28.14Consensus RatingBuy Company Overview Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production.Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy.Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity. The program is being explored for potential use in IgA nephropathy and other immune-related conditions.AI Generated. May Contain Errors. Read More Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCLYM MarketRank™: 2.40085967831 of 5 starsClimb Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 351st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialClimb Bio has a consensus price target of $28.14, representing about 206.9% upside from its current price of $9.17.Amount of Analyst CoverageClimb Bio has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Climb Bio are expected to decrease in the coming year, from ($0.75) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Climb Bio is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Climb Bio is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.88% of the float of Climb Bio has been sold short.Short Interest Ratio / Days to CoverClimb Bio has a short interest ratio ("days to cover") of 7.76.Change versus previous monthShort interest in Climb Bio has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.01 News SentimentClimb Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Climb Bio this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows5 people have added Climb Bio to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,367,000.00 in company stock.Percentage Held by Insiders2.60% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLYM Stock News HeadlinesClimb Bio (NASDAQ:CLYM) Stock Rating Reaffirmed as Outperform by Royal Bank Of CanadaNovember 20 at 1:42 AM | americanbankingnews.comClimb Bio, Inc. (CLYM) - What Are Researchers Thinking About This Stock?November 13, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 21 at 1:00 AM | Profits Run (Ad)Climb Bio Stock Earnings Estimates Raised by HC WainwrightNovember 13, 2026 | americanbankingnews.comClimb Bio (NASDAQ:CLYM) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedNovember 10, 2026 | americanbankingnews.comWedbush Adjusts Price Target on Climb Bio to $27 From $25, Keeps Outperform RatingNovember 5, 2026 | marketscreener.comMClimb Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMClimb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 5, 2026 | globenewswire.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $4.00 at the beginning of the year. Since then, CLYM stock has increased by 129.3% and is now trading at $9.17. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02. When did Climb Bio IPO? Climb Bio (CLYM) raised $80 million in an IPO on Thursday, August 5th 2021. The company issued 6,400,000 shares at $12.50 per share. Who are Climb Bio's major shareholders? Climb Bio's top institutional shareholders include RA Capital Management L.P. (17.25%), State Street Corp (3.15%), Great Point Partners LLC (1.36%) and Integral Health Asset Management LLC (1.19%). Insiders that own company stock include Ra Capital Management, LP, Stephen Basil Thomas and Emily Pimblett. View institutional ownership trends. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Climb Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Climb Bio investors own include NVIDIA (NVDA), Aclaris Therapeutics (ACRS), AeroVironment (AVAV), Cabaletta Bio (CABA), Definium Therapeutics (DFTX), TuHURA Biosciences (HURA) and Immunic (IMUX). Company Calendar Last Earnings11/05/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 9 days, CLYM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Price Target for Climb Bio$28.14 High Price Target$40.00 Low Price Target$18.00 Potential Upside/Downside+206.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.57% Return on Assets-29.55% Debt Debt-to-Equity RatioN/A Current Ratio26.58 Quick Ratio26.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.88 per share Price / Book2.36Miscellaneous Outstanding Shares58,740,000Free Float57,211,000Market Cap$538.65 million OptionableOptionable Beta0.01 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CLYM) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.